Table 2.
Erythrocyte miRNA marker panel sensitivities and specificities
| Cutoff at 85% specificity | Cutoff at 95% specificity | P valuesa | |
|---|---|---|---|
| Sensitivities, % (95% CI) | |||
| Colorectal cancer (n = 29) | 69 (49–85) | 66 (46–82) | |
| Stageb | 0.69 | ||
| T1, 2 (n = 16) | 67 (30–93) | 56 (21–86) | |
| T3, 4 (n = 10) | 65 (38–86) | 65 (38–86) | |
| Site | 0.0084 | ||
| Proximal (n = 16) | 50 (25–75) | 48 (20–70) | |
| Distal (n = 13) | 92 (64–100) | 92 (64–100) | |
| Advanced adenoma (n = 31) | 23 (10–41) | 13 (4–30) | |
| Site | 0.0432 | ||
| Proximal (n = 23) | 13 (3–34) | 4 (0–22) | |
| Distal (n = 8) | 50 (16–84) | 38 (9–76) | |
| Specificity, % (95% CI) | 85 (77–91) | 95 (90–98) |
a
Significant difference in sensitivities toward stages and sites were determined by Chi-square test-based sensitivities at 95% specificity cutoff
b
TNM stage data of three patients were unavailable